ArticleBiochemical genetics2026
Circulating Levels of miR-155 and CTBP1-AS2 as a Promising Biomarker for Early Detection of Diabetic Nephropathy.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomal MicroRNAs as theranostic tools in type 2 diabetes and its complications: mechanistic insights and clinical implications.Diabetology & metabolic syndrome · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is one of the most frequent complications of diabetes mellitus. Since the early diagnosis of DN is crucial to prevent the progression of the disease towards renal failure, many efforts have been made in recent years to introduce new diagnostic biomarkers. Recent studies suggest that non-coding RNAs could act as a novel diagnostic biomarker for the early detection and prediction of DN progress. Accordingly, in the current study we investigated the expression levels of miR-155 and CTBP1-AS2 in type 2 diabetes (T2D), DN patients and control subjects, and evaluated their diagnostic potential for DN. A total of 189 age and sex-matched subjects including 65 T2D patients with normo-albuminuria, 61 DN patients who had a history of albuminuria, and 63 control subjects were included in this case-control study. The expression levels of miR-155 and CTBP1-AS2 were determined using QRT-PCR. The results revealed that the expression level of miR-155 was significantly reduced in T2D patients. In addition, miR-155 level was significantly higher in DN patients with macroalbuminuria compared to DN patients with microalbuminuria and T2D patients with normo-albuminuria. The expression level of CTBP1-AS2 in T2D without proteinuria was higher than DN subjects with macroalbuminuria. The results also showed that there was a significant positive correlation between the miR-155 level with DBP, TG, TC, SCr and, BUN levels and a negative correlation with HDL-C and eGFR values. Deregulation levels of miR-155 and CTBP1-AS2 may represent useful novel diagnostic biomarkers for DN.
Indexed as
Identifiers
40632189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.